Current Addiction Reports
August 18, 2026
Michael J. Broman, Jhuma N. Acharya, Kaltum Ahmed et al.
Abstract Purpose of Review We highlight key findings and methodological issues from recent research on the abuse liability of classic psychedelics, utilizing a GRADE to assess the quality of the evidence. Recent Findings Studies using various designs suggest that classic psychedelics (e.g., psilocybin, LSD) have low abuse potential and less dependence liability than other drugs. However, public...
Life
August 14, 2026
Szabolcs Kéri
Clinical trials and naturalistic studies describe psychedelics under markedly different exposure conditions. This narrative review searched PubMed/MEDLINE, the Cochrane Library, ClinicalTrials.gov, and regulatory sources through 15 July 2026, and examined safety and outcomes across four dimensions of exposure: dose, frequency, person, and context. In screened adults receiving one to three...
Frontiers in Psychiatry
August 12, 2026
Anthony L. Back, Robert Bosnak
Psilocybin therapy in patients with cancer commonly produces vivid embodied and imaginal experiences that resist verbal description, yet most current integration approaches rely primarily on cognitive and verbal processing. We hypothesize that an approach to integration that directly engages this embodied register, without requiring translation into a verbal narrative, will enable patients to...
Zenodo (CERN European Organization for Nuclear Research)
August 11, 2026
Saanvi Gutta
preprint
Depression affects over 280 million people worldwide and remains one of the leading causes of disability and suicide. Existing treatments such as SSRIs and traditional psychotherapy often fail to provide relief, especially for individuals with treatment‑resistant depression. Recent clinical trials suggest that psychedelic‑assisted therapy using psilocybin or MDMA may offer rapid and durable...
bioRxiv (Cold Spring Harbor Laboratory)
August 10, 2026
Aedan O'Shea, Natasha L. Mason, Jacco Briede et al.
preprint
Abstract Psilocybin acutely alters neurotrophic, neurochemical, and immune markers, but the relationships between these responses and circulating microRNAs (miRNAs), i.e. non-coding RNAs that regulate post-transcriptional gene expression, remain unclear. In a randomized, double-blind, placebo-controlled study of 62 healthy adults who received psilocybin (0.17 mg/kg) or placebo, we previously...
Quality in Sport
August 7, 2026
M. Lewczuk, Natalia Trędota, Zuzanna Czyżewicz et al.
Background: Cluster headache is a severely disabling headache disorder. Despite the availability of acute and preventive therapies, treatment efficacy remains incomplete, leaving many athletes and other patients with insufficient symptom control leading to decreased quality of life and performance. Increasing interest has emerged in psychedelic compounds, particularly psilocybin, as potential...
Mental Health Weekly
August 7, 2026
Gary Enos
A team of researchers in Connecticut is advancing inquiry into the potential of psychedelics in mental health treatment through an ongoing study involving patients with complex conditions. A psilocybin trial that initially recruited military veterans, first responders and health care workers has shown promising results and is being expanded to include a broader population.
Asclepius International Journal of Scientific Health Science
August 7, 2026
Arthur Gomes Ferreira
A dependência da nicotina representa um dos principais desafios da saúde pública mundial, sendo responsável por elevadas taxas de morbimortalidade e associada ao desenvolvimento de doenças cardiovasculares, respiratórias e neoplásicas. Embora existam diferentes estratégias terapêuticas para a cessação do tabagismo, as elevadas taxas de recaída evidenciam a necessidade de novas abordagens...
JAMA Psychiatry
August 5, 2026
Michael Elliott, Olga Chernoloz
To the Editor In JAMA Psychiatry, Cubała et al. report that inhaled mebufotenin (GH001) reduced depression severity by 15.5 points more than placebo on the Montgomery-Åsberg Depression Rating Scale (MADRS) at 1 week, with 57.5% of patients achieving remission vs 0% in the placebo group. The effect size (d = −2.0) overwhelmingly surpasses those of selective serotonin reuptake inhibitors,...
Molecular Psychiatry
August 4, 2026
Kim P. C. Kuypers, Natasha L. Mason, Aurelie Carlier et al.
Women experience a disproportionate burden of affective and stress-related disorders, with symptom variability shaped by endocrine transitions across the menstrual cycle, pregnancy, postpartum, and menopause. Although psychedelic-assisted therapies are increasingly investigated for these conditions, hormonal state represents a largely unaccounted determinant of variability in exposure,...